Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityNo recent work listed

Zhuo Shao

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper

Papers 11

  1. Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. Co-author DOI 10.1093/bjs/znac457↗
  2. ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1. Co-author DOI 10.1038/s41389-022-00418-2↗
  3. A novel genomic instability-derived lncRNA signature to predict prognosis and immune characteristics of pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2022.970588↗
  4. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Co-author DOI 10.1002/ctm2.520↗
  5. The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients. Co-author DOI 10.3389/fonc.2021.717989↗
  6. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients. Co-author DOI 10.1038/s41416-019-0704-2↗
  7. OCIAD1 promoted pancreatic ductal adenocarcinoma migration by regulating ATM. Co-author DOI 10.1016/j.pan.2019.01.009↗
  8. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer. Co-author DOI 10.1096/fj.201800617r↗
  9. A SLC24A2 Gene Variant Uncovered in Pancreatic Ductal Adenocarcinoma by Whole Exome Sequencing. First author DOI 10.1620/tjem.241.287↗
  10. Downregulation of CPE regulates cell proliferation and chemosensitivity in pancreatic cancer. Co-author DOI 10.1007/s13277-014-2564-y↗
  11. High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11605-012-1921-7↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Jin · 8 shared papers, 2012–2023 · strength 0.70
  2. Suizhi Gao · 5 shared papers, 2019–2023 · strength 0.52
  3. Shiwei Guo · 5 shared papers, 2019–2023 · strength 0.52
  4. Xiaohan Shi · 5 shared papers, 2019–2023 · strength 0.52
  5. Kailian Zheng · 4 shared papers, 2019–2023 · strength 0.41
  6. Xiongfei Xu · 3 shared papers, 2020–2023 · strength 0.34
  7. Bo Li · 3 shared papers, 2020–2023 · strength 0.34
  8. Shuo Shen · 3 shared papers, 2020–2023 · strength 0.34
  9. Bin Song · 3 shared papers, 2019–2023 · strength 0.32
  10. Guoxiao Zhang · 2 shared papers, 2021–2023 · strength 0.23
  11. Jing Shen · 2 shared papers, 2020–2021 · strength 0.21
  12. Shenming Li · 1 shared paper, 2022 · strength 0.15
  13. Xingmao Zhang · 1 shared paper, 2022 · strength 0.15
  14. Chenggang Li · 1 shared paper, 2022 · strength 0.15
  15. Hua Fan · 1 shared paper, 2022 · strength 0.15
  16. Jin Ding · 1 shared paper, 2022 · strength 0.15
  17. Huijie Yang · 1 shared paper, 2022 · strength 0.15
  18. Yang Xiao · 1 shared paper, 2022 · strength 0.15
  19. Lingyu Zhu · 1 shared paper, 2023 · strength 0.13
  20. Jian Wang · 1 shared paper, 2023 · strength 0.13
  21. Xiaoyi Yin · 1 shared paper, 2023 · strength 0.13
  22. Peng Cheng · 1 shared paper, 2023 · strength 0.13
  23. Gang Li · 1 shared paper, 2021 · strength 0.10
  24. Wei Jing · 1 shared paper, 2021 · strength 0.10
  25. Hao Qin · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.